Go Pro
OTCMKTS:EDTXF

Spectral Diagnostics Q1 2026 Earnings Report

Spectral Diagnostics logo
$0.94 0.00 (0.00%)
As of 07/9/2026 02:59 PM Eastern

Spectral Diagnostics EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Spectral Diagnostics Revenue Results

Actual Revenue
$0.64 million
Expected Revenue
$0.54 million
Beat/Miss
Beat by +$99.00 thousand
YoY Revenue Growth
N/A

Spectral Diagnostics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Spectral Diagnostics' next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules.

Conference Call Resources

Spectral Diagnostics Earnings Headlines

Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics (OTCMKTS:EDTXF) and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

View Spectral Diagnostics Profile